CL2015001701A1 - Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros. - Google Patents

Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros.

Info

Publication number
CL2015001701A1
CL2015001701A1 CL2015001701A CL2015001701A CL2015001701A1 CL 2015001701 A1 CL2015001701 A1 CL 2015001701A1 CL 2015001701 A CL2015001701 A CL 2015001701A CL 2015001701 A CL2015001701 A CL 2015001701A CL 2015001701 A1 CL2015001701 A1 CL 2015001701A1
Authority
CL
Chile
Prior art keywords
procedure
ophthalmological
regorafenib
cataracts
polymorph
Prior art date
Application number
CL2015001701A
Other languages
English (en)
Inventor
Degenfeld Georges Von
Claudia Hirth-Dietrich
Michael Böttger
Julia Freundlieb
Joerg Keldenich
Jürgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Rield
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CL2015001701A1 publication Critical patent/CL2015001701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
CL2015001701A 2012-12-21 2015-06-17 Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros. CL2015001701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12198892 2012-12-21

Publications (1)

Publication Number Publication Date
CL2015001701A1 true CL2015001701A1 (es) 2015-10-16

Family

ID=47458742

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001701A CL2015001701A1 (es) 2012-12-21 2015-06-17 Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros.

Country Status (27)

Country Link
US (2) US20140179745A1 (es)
EP (1) EP2934481A1 (es)
JP (1) JP2016507505A (es)
KR (1) KR20150100670A (es)
CN (1) CN104955443A (es)
AP (1) AP2015008493A0 (es)
AR (1) AR094104A1 (es)
AU (1) AU2013364004A1 (es)
BR (1) BR112015014078A2 (es)
CA (1) CA2895804A1 (es)
CL (1) CL2015001701A1 (es)
CR (1) CR20150327A (es)
CU (1) CU20150063A7 (es)
DO (1) DOP2015000155A (es)
EA (1) EA201500669A1 (es)
EC (1) ECSP15026386A (es)
IL (1) IL238791A0 (es)
MA (1) MA38215A1 (es)
MX (1) MX2015007488A (es)
PE (1) PE20151784A1 (es)
PH (1) PH12015501407A1 (es)
SG (1) SG11201503838WA (es)
TN (1) TN2015000280A1 (es)
TW (1) TW201431568A (es)
UY (1) UY35183A (es)
WO (1) WO2014100797A1 (es)
ZA (1) ZA201505196B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458031A4 (en) * 2016-05-16 2020-01-22 Delivra Inc. TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS
CN112834485B (zh) * 2021-02-07 2022-03-29 西南交通大学 激光诱导击穿光谱元素定量分析的一种非定标方法
KR102413226B1 (ko) 2021-08-26 2022-06-23 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 항노화 조성물
KR20230166353A (ko) 2022-05-30 2023-12-07 (주) 레비레스코 감태 추출물, 귤피 추출물, 및 녹차 추출물을 유효성분으로 포함하는 자외선에 대한 세포 보호용 또는 mmp-1 발현 억제용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) * 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
PL1885336T3 (pl) 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
EP1893216A4 (en) 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
US20080293691A1 (en) 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
EP1962828A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating inflammatory skin, eye and/or ear diseases
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN102573477A (zh) 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
JP5998213B2 (ja) * 2011-06-28 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ レゴラフェニブを含有する眼科用局所医薬組成物

Also Published As

Publication number Publication date
JP2016507505A (ja) 2016-03-10
US20150328145A1 (en) 2015-11-19
DOP2015000155A (es) 2015-08-31
EA201500669A1 (ru) 2015-12-30
MX2015007488A (es) 2015-09-04
AP2015008493A0 (en) 2015-05-31
IL238791A0 (en) 2015-06-30
AU2013364004A1 (en) 2015-06-04
AR094104A1 (es) 2015-07-08
WO2014100797A1 (en) 2014-06-26
MA38215A1 (fr) 2017-01-31
CR20150327A (es) 2015-09-14
TW201431568A (zh) 2014-08-16
PH12015501407A1 (en) 2015-09-07
ZA201505196B (en) 2017-11-29
CA2895804A1 (en) 2014-06-26
UY35183A (es) 2014-07-31
SG11201503838WA (en) 2015-07-30
TN2015000280A1 (en) 2016-10-03
ECSP15026386A (es) 2016-01-29
BR112015014078A2 (pt) 2018-05-15
CU20150063A7 (es) 2015-11-27
KR20150100670A (ko) 2015-09-02
PE20151784A1 (es) 2015-11-25
EP2934481A1 (en) 2015-10-28
CN104955443A (zh) 2015-09-30
US20140179745A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2013002552A1 (es) Uso de una combinación de un compuesto derivado de 3-fenil-2-[1-(9h-purin-6-ilamino)alquil]quinazolin-4-ona y uno o más agentes terapéuticos seleccionados entre bendamustina, rituximab, lenalidomida y ofatumumab, para el tratamiento del cáncer.
MY171920A (en) Prevention and treatment of ocular conditions
CL2014001049A1 (es) Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica.
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EP2671586A4 (en) PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CL2015001701A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros.
IN2014CN03123A (es)
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
EP3763815A4 (en) THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos